I-MOVE, influenza vaccine effectiveness

Project description

The I-MOVE (Influenza – Monitoring Vaccine Effectiveness in Europe) network aims to measure influenza vaccine effectiveness (VE) in Europe. The I-MOVE network includes a multicentre study at primary care level to measure influenza VE and a multicentre study carried out at hospital level to measure VE against severe influenza. Within the I-MOVE network we also carry out studies measuring the impact of influenza vaccination campaigns.

Context situation

The project started in 2007 and has carried out multicentre and other studies since the 2008–9 influenza season. The network consists of 29 partners including ECDC, WHO-EURO, regional and national public health institutes, hospitals, small and medium enterprises, and universities from 15 European Union/European Economic Area Member States. The I-MOVE network measures VE in a way that is scientifically and financially independent from vaccine manufacturers.

Sponsor or customer

ECDC, European Commission (European Union´s Horizon 2020 research and innovation programme under grant agreement Nº 634446), WHO-EUROPE, participating member states, Epiconcept

Dates of the project

November 2007 - June 2022

Website

Project activities

Development of generic protocols to measure influenza vaccine effectiveness studies

test-negative design, cohort, screening method, impact studies.

Coordination of multicentre, multicountry surveillance and research networks

review of protocols, organisation of scientific conferences and technical workshops, training

Pooled analysis to provide vaccine effectiveness at European level

data management, data validation, development of scripts, report writing, scientific communication

Scientific publications

I-MOVE/I-MOVE+ study team, 2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children.

Kissling E, Valenciano M, Pozo F, Vilcu A-M, Reuss A, Rizzo C, et al

Influenza Other Resp Viruses. Accepted Author Manuscript.doi:10.1111/irv.125207

Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020.

Rose Angela, Kissling Esther, Emborg Hanne-Dorthe, Larrauri Amparo, McMenamin Jim, Pozo Francisco, Trebbien Ramona, Mazagatos Clara, Whitaker Heather, Valenciano Marta, European IVE group

Euro Surveill. 2020;25(10):pii=2000153.

Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine.

Rose AMC, Kissling E, Gherasim A, et al.

Influenza Other Respir Viruses. 2020 May;14(3):302-310. DOI: 10.1111/irv.12714. PMID: 32022450; PMCID: PMC7182608

Interim 2019/20 influenza vaccine effectiveness six European studies, September 2019 to January 2020

Rose A, Kissling E, Emborg H-D, Larrauri A, McMenamin J, Pozo F et al.

Euro Surveil. 2020;25(10):pii=2000153.

Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort. Euro Surveill. 2019;24(48):pii=1900604.

Kissling E, Pozo F, Buda S, Vilcu A-M, Gherasim A, Brytting M, Domegan L, Gómez V, Meijer A, Lazar M, Vučina Vesna V, Dürrwald R, van der Werf S, Larrauri A, Enkirch T, O’Donnell J, Guiomar R, Hooiveld M, Petrović G, Stoian E, Penttinen P, Valenciano M, I-MOVE primary care study team

Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019

Kissling E, Rose A, Emborg HD, Gherasim A, Pebody R, Pozo F, et al., European IVE group

Euro Surveill.2019;24(8):pii=1900121

Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18).

Kissling E, Pozo F, Buda S, Vilcu AM, Rizzo C, Gherasim A, et al.

Vaccine X. 2019;3:100042

Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons. Euro Surveill. 2019;24(45):pii=1900268.

Machado A, Mazagatos C, Dijkstra F, Kislaya I, Gherasim A, McDonald Scott A, Kissling E, Valenciano M, Meijer A, Hooiveld M, Nunes B, Larrauri A

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Rondy M, Kissling E, Emborg H-D, Gherasim A, Pebody R, Trebbien R, Pozo F, Larrauri A,McMenamin J, Valenciano M, I-MOVE/I-MOVE+ group.

Euro Surveill. 2018;23(9):pii=18-00086

Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically-attended influenza: results of the European I-MOVE multicentre test-negative case-control study, 2011/12-2016/17. Influenza Other Respir Viruses

Valenciano M, Kissling E, Larrauri A, Nunes B, Pitigoi D, O Donnell J, et al, I-MOVE primary care multicentre case-control team

2018;1-15.doi: 10.1111/irv.12562

Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.

Kissling E, Rondy M, I-MOVE/I-MOVE+ study team.

Euro Surveill. 2017;22(7):pii=30464.

Early influenza vaccine effectiveness results 2015-16: I-MOVE multicentre case-control study

Kissling E, Valenciano M.

Euro Surveill. 2016;21(6):pii=30134.

Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case–Control Study, Europe 2014/15.

Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth J K, Domegan L, Pitigoi D, Machado A, Paradowska-Stankiewicz I A, Bella A, Larrauri A, Ferenczi A, O´Donell J.

Euro Surveill. 2016;21(7):pii=30139.

Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?

Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al, I-MOVE case–control study team. I-MOVE multicentre case–control study 2010/11 to 2014/15

Euro Surveill. 2016;21(16):pii=30201

Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).

Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, Pitigoi D, Machado A, Pozo F; I-MOVE Multicentre Case Control Study Team. The European I-MOVE Multicentre 2013-2014 Case-Control Study.

Vaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012. Epub 2015 Apr 28. PMID: 25936723

Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case–control study, influenza season 2012/13.

Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen J M, Nunes B, Rogalska J, Pitigoi D, Paradowska-Stankiewicz I, Reuss A, Jiménez-Jorge S, Daviaud I, Guiomar R, O’Donnell J, Necula G, Głuchowska M, Moren A.

Euro Surveill. 2014;19(6):pii=20701. https://doi.org/10.2807/1560-7917.ES2014.19.6.20701

Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case–control study, 2011/12.

Kissling E, Valenciano M, I-MOVE case–control studies team Collective.

Euro Surveill. 2012;17(15):pii=20146. https://doi.org/10.2807/ese.17.15.20146-en

I-MOVE: a European network to measure the effectiveness of influenza vaccines.

Valenciano M, Ciancio B; I-MOVE study team

Euro Surveill. 2012 Sep 27;17(39):20281. doi: 10.2807/ese.17.39.20281-en.

Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study

Kissling E, Valenciano M; I-MOVE case-control studies team

Euro Surveill. 2011 Mar 17;16(11):19818. doi: 10.2807/ese.16.11.19818-en.

Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study.

Kissling E, Valenciano M; I-MOVE case-control studies team

Euro Surveill. 2011 Mar 17;16(11):19818. doi: 10.2807/ese.16.11.19818-en. PMID: 21435329.

Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.

Valenciano M, Kissling E, Cohen JM, et al.

Plos Medicine. 2011 Jan;8(1):e1000388. DOI: 10.1371/journal.pmed.1000388. PMID: 21379316; PMCID: PMC3019108.

Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks

Valenciano M, Kissling E, Ciancio BC, Moren A

Vaccine. 2010 Oct 28;28(46):7381-8. doi: 10.1016/j.vaccine.2010.09.010. Epub 2010 Sep 17. PMID: 20851086

First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States

Valenciano M, Ciancio B C, Moren A, the influenza vaccine effectiveness working group Collective

Euro Surveill. 2008;13(43):pii=19015.

Find all our scientific publications

Référencement Centrales d'achats

Hébergement de données de santé

Nous sommes Hébergeur de Données de Santé (HDS) à caractère personnel depuis 2012 avec la certification ISO 27001/HDS depuis 2019.

Engagement et éthique

Découvrez nos engagements et valeurs dans notre charte